KNSA Kiniksa Pharmaceuticals PE ratio, current and historical analysis
The current price-to-earnings ratio of KNSA can't be determined, as the TTM EPS of -$0.13 is negative. The most recent PE ratio recorded for Kiniksa Pharmaceuticals was 164.42 in March 2024.
KNSA PE ratio history
Over the last three years, the average PE ratio of Kiniksa Pharmaceuticals has been 45.35. In the past three years, KNSA's PE ratio was at its highest in the Mar 2024 quarter at 164.42, with a price of $19.73 and an EPS of $0.12. The Mar 2023 quarter recorded the bottom point at 3.82, with a price of $10.76 and an EPS of $2.82.
Kiniksa Pharmaceuticals PE ratio by year
Maximum annual increase: 1,446.74% in 2023
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 87.7 | 1,446.74% |
| 2022 | 5.67 | N/A |
| 2021 | N/A | N/A |
| 2020 | N/A | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
KNSA average PE ratio chart
KNSA PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| ORMP Oramed Pharmaceuticals Inc | 21 | $93.12M |
| OLMA Olema Pharmaceuticals Inc | N/A | $450.93M |
| OMER Omeros Corp | N/A | $447.95M |
| OMGA Omega Therapeutics Inc | N/A | $42.96M |
| ONCT Oncternal Therapeutics Inc | N/A | $3.43M |
| ONVO Organovo Holdings Inc | N/A | $5.38M |
| ORIC Oric Pharmaceuticals Inc | N/A | $643.57M |
| KNSA Kiniksa Pharmaceuticals Ltd | N/A | $1.52B |
Frequently asked questions
What is Kiniksa Pharmaceuticals's PE ratio?
The current price to earnings ratio of KNSA can't be calculated, as its EPS of -$0.13 is negative.
What is the 3-year average PE ratio for Kiniksa Pharmaceuticals (KNSA)?
Over the last 3 years, the average price to earnings ratio for KNSA stock is 45.35.
What is the 5-year average PE ratio for Kiniksa Pharmaceuticals (KNSA)?
Over the last 5 years, the average price to earnings ratio for KNSA stock is 45.35.
What is the highest PE ratio for KNSA?
Over the last three years, the quarterly PE ratio reached a historic high of 164.42 in the Mar 2024 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.